NEW YORK (Reuters Health) – Following steroid withdrawal, the anti-CD20 monoclonal antibody rituximab is effective in maintaining long-term remission of steroid-dependent nephrotic syndrome (SDNS) while
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok
